Biogen

NASDAQ:BIIBBiotech

Cambridge, MA, United States · Est. 1978 · 7,500 employees

Pioneer in neuroscience, advancing innovative therapies.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

497

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 6 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

22 drugs in development

Approved5

Phase 38

Phase 27

Phase 16

Preclinical11

By Therapeutic Area

top 6

Neurology

1333%

Musculoskeletal

38%

Rare Disease

25%

Immunology

25%

Cardiovascular

25%

Psychiatry

25%

R&D Momentum

73/100

Pipeline Velocity

41/100

Trial Completion Rate

75/100

Pipeline Concentration

20/100

Pipeline Freshness

74/100

Strategic Signals

↗Active in Rare Disease but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 19, 2026

Recruiting

A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants With Late Isolated Microvascular Inflammation (MVI)

Sep 18, 2026

Active, not recruiting

A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

Sep 17, 2026

Recruiting

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL)

Sep 12, 2026

Active, not recruiting

Pediatric Patients With Spinal Muscular Atrophy in China: A Nationwide Registry

Sep 12, 2026

Enrolling by invitation

A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus

Sep 10, 2026

Enrolling by invitation

An Open-Label Long-Term Extension Study of Felzartamab in Participants With Antibody-Mediated Rejection or Microvascular Inflammation Previously Enrolled in TRANSCEND or TRANSPIRE

Sep 9, 2026

Completed

Prospective, Observational Survey Study Assessing Effectiveness of Zuranolone in Improving PPD Symptoms in the Real-world Setting

Sep 9, 2026

Recruiting

A Longitudinal Online Survey of Patient-Reported Changes in Postpartum Depression Symptoms Following Zuranolone Use

4 more events

Sep 5, 2026TrialA Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab Compared to Placebo in Adult Participants With Graves' Disease

Sep 4, 2026TrialAn Open-Label, Phase 1, Study to Evaluate the Pharmacokinetics, Safety, Tolerability, Pharmacodynamics, and Efficacy of Omaveloxolone in Participants ≥2 to <16 Years of Age With Friedreich's Ataxia

Sep 4, 2026TrialA Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)

Sep 4, 2026TrialAn Open Label Study to Assess the Pharmacokinetic Profile of Nusinersen (BIIB058) Administered Via the ThecaFlex DRx™ System (PIERRE-PK)

Details

Company Info

Company Overview

$23.0B

Mkt Cap

$9.8B

Revenue

$2.3B

Cash

CEOChristopher Viehbacher

Founded1978

Employees7,500

HQCambridge, MA, United States

ExchangeNASDAQ:BIIB

Websitebiogen.com

LinkedInCompany Page

Therapeutic Focus

HematologyNeurologyCardiovascularPsychiatryRare DiseaseMusculoskeletalOtherImmunologyGastroenterologyOncologyNephrologyOphthalmologyMetabolic & Endocrine

Patent Expirations

13 patent groups across drugs · Source: FDA Orange Book

DrugExpires

SpinrazaJul 11, 2027 TecfideraFeb 7, 2028 Skyclarys5 patentsApr 20, 2029 Spinraza3 patentsJun 17, 2030 Skyclarys2 patentsApr 24, 2033 Vumerity3 patentsSep 20, 2033 SpinrazaJan 9, 2034 Zurzuvae3 patentsApr 17, 2034

5 more

Tecfidera8 patentsMar 13, 2035 Qalsody3 patentsApr 1, 2035 SpinrazaSep 11, 2035 SpinrazaMar 4, 2036 Zurzuvae2 patentsAug 23, 2037

Recent SEC Filings

8-KJul 29, 2026

8-K

8-KJul 1, 2026

8-K

EX-99.2Mar 31, 2026

BIOGEN INC. (BIIB) (CIK 0000875045)

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(2 drugs)

—

Cardiovascular(2 drugs)

Gastroenterology(1 drug)

—

Gastroenterology(1 drug)

Hematology(1 drug)

—

Hematology(1 drug)

Immunology(2 drugs)

—

Immunology(2 drugs)

Musculoskeletal(3 drugs)

—

Musculoskeletal(3 drugs)

Nephrology(1 drug)

—

Nephrology(1 drug)

Neurology(13 drugs)

—

Neurology(13 drugs)

Oncology(1 drug)

—

Oncology(1 drug)

Ophthalmology(1 drug)

—

Ophthalmology(1 drug)

Psychiatry(2 drugs)

—

Psychiatry(2 drugs)

Rare Disease(2 drugs)

—

Rare Disease(2 drugs)

Unknown / Other(10 drugs)

Regulatory

Regulatory Timeline

20202 events

FDAJun 16

Spinraza — SPINRAZA

Application NDA209531

FDAFeb 5

Tecfidera — TECFIDERA

Application NDA204063

20211 event

FDAJan 29

Tecfidera — TECFIDERA

Application NDA204063

20223 events

FDASep 29

Tecfidera — TECFIDERA

Application NDA204063

FDASep 29

Tecfidera — TECFIDERA

Application NDA204063

FDAFeb 10

Tecfidera — TECFIDERA

Application NDA204063

20238 events

FDADec 13

Tecfidera — TECFIDERA

Application NDA204063

FDAOct 31

Zurzuvae — ZURZUVAE

Application NDA217369 (NDA)

FDAAug 4

Zurzuvae — ZURZUVAE

Application NDA217369

FDAApr 25

Qalsody — QALSODY

Application NDA215887 (NDA)

FDAApr 25

Qalsody — QALSODY

Application NDA215887

FDAFeb 28

Skyclarys — SKYCLARYS

Application NDA216718 (NDA)

FDAFeb 17

Spinraza — SPINRAZA

Application NDA209531

FDAFeb 10

Tecfidera — TECFIDERA

Application NDA204063

20244 events

FDAJul 31

Zurzuvae — ZURZUVAE

Application NDA217369

FDAApr 10

Spinraza — SPINRAZA

Application NDA209531

FDAApr 10

Spinraza — SPINRAZA

Application NDA209531

FDAMar 12

Tecfidera — TECFIDERA

Application NDA204063

20265 events

SECJul 29

8-K

Accession: 0000875045-26-000073

SECJul 1

8-K

Accession: 0000875045-26-000068

FDAApr 20

Zurzuvae — ZURZUVAE

Application NDA217369

SECMar 31

BIOGEN INC. (BIIB) (CIK 0000875045)

Accession: 000-19311

FDAMar 27

Spinraza — SPINRAZA

Application NDA209531

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)